NEW YORK – Four years into implementation of the federal No Surprises Act (NSA), claims for clinical lab testing comprise a substantial proportion of bills being disputed under the law. And in the ...

This story has been updated to correct a comment by Diana Marcella Cardona that was mischaracterized in the original version. We regret the error. NEW YORK ...

NEW YORK – Based on data generated in the National Lung Screening Trial (NLST) cohort, cancer testing firm Mercy BioAnalytics believes its lung cancer early detection assay can identify cancers missed ...

NEW YORK – During a webcast presentation at the 44 th Annual JP Morgan Healthcare Conference in San Francisco on Monday, Qiagen CEO Theirry Bernard projected a near-term revival of lab equipment ...

ANAHEIM, Calif. — Point-of-care firm Kompass Diagnostics took first place in the Disruptive Technology Award Competition at the Association for Diagnostics & Laboratory Medicine's annual meeting here ...

NEW YORK – Guardant Health's stock was up as much as 9 percent on Wednesday on the Nasdaq after insurer UnitedHealthcare announced it would cover the firm's Shield screening test for colorectal cancer ...

NEW YORK – Waters said Wednesday that it has received US Food and Drug Administration 510(k) approval for its automated BD Bactec FXI Culture System. According to Waters, clinical study data shows ...

NEW YORK — Canadian diagnostics developer Nanostics said Thursday that it has received a C$3.8 million (US$2.8 million) grant from Genome Canada and Genome Alberta to boost the adoption of its ...

NEW YORK – After a bumpy 2025 thanks to declining COVID-19 testing and difficulties related to volume-based procurement in China, Abbott is prepared for an "acceleration" of its diagnostics business ...

NEW YORK — Diagnostics developer BioAffinity said on Wednesday that it has priced a $3.2 million public stock offering. According to the San Antonio-based firm, it intends to sell 4 million shares of ...

NEW YORK — In June, the US Food and Drug Administration cleared a dozen in vitro diagnostic assays to detect infectious pathogens, acute and chronic diseases, and other health markers from ...

C2N Diagnostics has launched its Research Use Only (RUO) C2N eMTBR-tau243 and C2N %p-tau MAA plasma tests for research into Alzheimer's disease. The C2N eMTBR-tau243 test measures the microtubule ...